Literature DB >> 26970119

Precision oncology: a strategy we were not ready to deploy.

Tito Fojo1.   

Abstract

Mesh：

Year:  2016        PMID： 26970119     DOI： 10.1053/j.seminoncol.2016.01.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  11 in total

Review 1.  Perspective on Precision Medicine in Oncology.

Authors:  Tali M Johnson
Journal:  Pharmacotherapy       Date:  2017-08-07       Impact factor: 4.705

2.  Precision Oncology beyond Targeted Therapy: Combining Omics Data with Machine Learning Matches the Majority of Cancer Cells to Effective Therapeutics.

Authors:  Michael Q Ding; Lujia Chen; Gregory F Cooper; Jonathan D Young; Xinghua Lu
Journal:  Mol Cancer Res       Date:  2017-11-13       Impact factor: 5.852

Review 3.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

4.  Functional precision cancer medicine-moving beyond pure genomics.

Authors:  Anthony Letai
Journal:  Nat Med       Date:  2017-09-08       Impact factor: 53.440

5.  Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

Authors:  John Marquart; Emerson Y Chen; Vinay Prasad
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

6.  Precision oncology: separating the wheat from the chaff.

Authors:  Jordi Remon; Rodrigo Dienstmann
Journal:  ESMO Open       Date:  2018-10-30

Review 7.  Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes.

Authors:  Mariano Bizzarri; Valeria Fedeli; Noemi Monti; Alessandra Cucina; Maroua Jalouli; Saleh H Alwasel; Abdel Halim Harrath
Journal:  EPMA J       Date:  2021-10-07       Impact factor: 6.543

Review 8.  The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology.

Authors:  Margaret Morash; Hannah Mitchell; Himisha Beltran; Olivier Elemento; Jyotishman Pathak
Journal:  J Pers Med       Date:  2018-09-17

9.  Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.

Authors:  Lelia Maria de Almeida Carvalho; Sandra de Oliveira Sapori Avelar; Alyson Haslam; Jennifer Gill; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-11-01

10.  Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape.

Authors:  Tito Fojo; Lyn Huff; Thomas Litman; Kate Im; Maureen Edgerly; Jaydira Del Rivero; Stefania Pittaluga; Maria Merino; Susan E Bates; Michael Dean
Journal:  BMC Med Genomics       Date:  2020-11-04       Impact factor: 3.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.